Novartis AG ROE 2006-2018 | NVS

Current and historical return on equity (ROE) values for Novartis AG (NVS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Novartis AG ROE for the three months ending September 30, 2018 was 15.81%.
Novartis AG ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $13.39B $78.02B 17.83%
2018-06-30 $13.85B $76.90B 18.80%
2018-03-31 $8.06B $71.21B 11.21%
2017-12-31 $7.70B $74.23B 10.84%
2017-09-30 $6.68B $72.37B 9.38%
2017-06-30 $6.54B $69.98B 9.10%
2017-03-31 $6.37B $67.65B 8.78%
2016-12-31 $6.71B $74.89B 9.12%
2016-09-30 $6.81B $75.07B 9.18%
2016-06-30 $6.76B $72.53B 9.06%
2016-03-31 $6.79B $71.89B 8.91%
2015-12-31 $17.78B $77.12B 23.01%
2015-09-30 $18.22B $76.79B 24.06%
2015-06-30 $19.56B $78.83B 26.29%
2015-03-31 $20.27B $76.44B 28.04%
2014-12-31 $10.21B $70.84B 14.42%
2014-09-30 $10.75B $71.42B 14.99%
2014-06-30 $9.76B $70.52B 13.57%
2014-03-31 $9.72B $70.34B 13.56%
2013-12-31 $9.18B $74.47B 12.95%
2013-09-30 $9.13B $72.18B 13.13%
2013-06-30 $9.29B $69.63B 13.60%
2013-03-31 $9.42B $67.15B 14.07%
2012-12-31 $9.27B $69.26B 14.05%
2012-09-30 $8.29B $67.21B 12.72%
2012-06-30 $8.36B $64.24B 12.89%
2012-03-31 $8.42B $63.20B 12.83%
2011-12-31 $8.94B $65.94B 13.52%
2011-09-30 $10.11B $66.14B 15.07%
2011-06-30 $9.92B $67.09B 14.78%
2011-03-31 $9.63B $65.34B 14.98%
2010-12-31 $9.79B $69.77B 15.86%
2010-09-30 $9.93B $66.22B 16.92%
2010-06-30 $9.75B $55.82B 17.59%
2010-03-31 $9.37B $55.22B 17.32%
2009-12-31 $8.40B $57.46B 16.19%
2009-09-30 $7.63B $53.31B 15.23%
2009-06-30 $7.63B $50.49B 15.41%
2009-03-31 $7.84B $46.23B 15.76%
2008-12-31 $8.20B $50.44B 16.22%
2008-09-30 $7.56B $50.74B 15.04%
2008-06-30 $12.34B $51.61B 24.70%
2008-03-31 $12.09B $49.27B 25.22%
2007-12-31 $11.95B $49.40B 26.10%
2007-09-30 $12.70B $49.49B 29.03%
2007-06-30 $7.70B $43.66B 18.77%
2007-03-31 $7.40B $40.50B 18.78%
2006-12-31 $7.18B $41.29B 19.03%
2006-09-30 $6.87B $38.59B 19.26%
2006-06-30 $6.66B $37.16B 19.62%
2006-03-31 $6.60B $33.75B 20.44%
2005-12-31 $6.13B $33.16B 19.65%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $204.655B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14